logo
Share SHARE
FONT-SIZE Plus   Neg

Amended: Ampio Pharma Says FDA Accepts IND For Diabetic Macular Edema Drug

Corrects Headline & 1st Para to Indicate FDA Accepts IND for Eye Drug

Ampio Pharmaceuticals, Inc. (AMPE) Tuesday said the FDA has accepted its IND for Optina, an oral drug used in the treatment of diabetic macular edema, or DME.

Optina had been given 505-b-2 status by FDA in July, 2012. Drugs designated under this pathway can be approved on a single trial.

DME is a devastating complication of diabetes and is manifested by local and systemic inflammation. Optina also has the potential to treat other systemic complications of diabetes such as nephropathy, said the company.

The planned multi-center trial, scheduled to begin in the first quarter, is designed to evaluate the safety and efficacy of oral Optina compared with placebo given over a period of 12 weeks in adult patients with DME.

Patients will be randomized to receive one of two doses of Optina per day or placebo. Interim analysis will occur after patients have completed 4 weeks of initial treatment.

Following the 12 week active treatment period, there will be a further 4 week washout period to determine regression of treatment effect.

The primary endpoint is improvement in visual acuity, defined by responder status, compared to placebo, while secondary endpoints include measurements of changes in VA and central macular thickness, tolerability etc.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple and Hertz Global Holdings Inc. will work hand in hand to develop self driving vehicles. Bloomberg reported that Apple will hand over six Lexus SUVs to Hertz subsidiary Donlen fleet management unit for software testing. The leasing agreement between Apple and Hertz for a small fleet of vehicles was revealed by the California Department of Motor vehicles. The document listed Donlen as the le Apple Inc. has acquired German computer vision company SensoMotoric Instruments, a maker of eye-tracking glasses and systems, according to media reports. Financial terms of the deal are not known. The acquisition is expected to help Apple develop software that will be built into future versions of the iPhone or other new hardware. Western Digital Corp. and U.S. private equity firm KKR & Co. LP have resubmitted an offer for Toshiba Corp.'s flash memory chip unit, according to media reports on Tuesday. The new offer is said to be around 2 trillion yen. Western Digital's re-submission of a bid comes amid speculation that Toshiba might sign an agreement by Wednesday to sell the business to a Japanese-led consortium.
comments powered by Disqus
Follow RTT